StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.95−0.05 (-1.67%)

Close on Nov 17, 2026Market cap $268.41MP/E –Yield –

SAB Biotherapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

SAB Biotherapeutics's price to sales ratio was 11.9× on Apr 30, 2025, against 17.7× a year earlier. Over the last 4 years it ranged from 0.6× to 23.1×, with a median of 6.2×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Apr 30, 202511.9×−11.2
2024Dec 31, 202423.1×+7.6
2023Dec 29, 202315.5×+14.1
2022Dec 30, 20221.4×+0.5
2021Dec 31, 20210.8×–

More SAB Biotherapeutics figures

See a number that looks wrong?